Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1991-01-02
1992-03-24
Dentz, Bernard
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
546121, A61K 31435, C07D 4704
Patent
active
050989111
ABSTRACT:
The invention relates to a novel crystalline form, containing water of crystallization, of 4-(5,6,7,8-tetrahydroimidazol[1,5-a] pyridin-5-yl)-benzonitrile hydrochloride of formula Ia ##STR1## and to a process for the preparation thereof. The novel crystalline form is distinguished by excellent storage stability.
REFERENCES:
patent: 4617307 (1991-10-01), Browne
Lang et al., Cancer Res. 31, 220, Abs. 1305 (1990) Corresponding to Poster No. 1305.
Santen et al., J. Clin. Endocrin., and Metabolism 68, 99-106 (1989).
Dowsett, et al., J. Endocrinol. 119 (Supp) Abs. 123 (1988).
Santen, et al., Clin. Res. 37, 535A (1989).
Demers, et al., J. Clin Endocrinol. 70, 1162-1166 (1990).
Juniewicz, et al., Ann. NY Acad. Sci. 513, 337-339 (1987).
Schieweck, et al., Proc. Am. Assoc. Cancer Res. 30, 303 (1989).
Oral Presentation of Hanagan, 6 Oct. 1988 Pretoria, South Africa.
Lamberts, et al., Chem. Abs. 111, 187280s (1989).
Santen, et al., Abstract of Oral presentation at 70th Annual Meeting of the Endocrine Society.
Ciba-Geigy Corporation
Dentz Bernard
Fishman Irving M.
Kaiser Karen G.
LandOfFree
Hemihydrate of 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)b does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hemihydrate of 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)b, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hemihydrate of 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)b will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2010458